RXRX
Recursion Pharmaceuticals Inc
NASDAQ: RXRX · HEALTHCARE · BIOTECHNOLOGY
$3.46
+4.85% today
Updated 2026-04-30
Market cap
$1.80B
P/E ratio
—
P/S ratio
24.12x
EPS (TTM)
$-1.44
Dividend yield
—
52W range
$3 – $7
Volume
13.8M
Recursion Pharmaceuticals Inc (RXRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+4.7%
Last 4 quarters
Revenue YoY growth
+687.8%
Most recent quarter
EPS YoY growth
+60.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.1%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-7.6%
2025-11-05
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $-0.21 | +30.0% | $3.53 | $3.77 | +6.8% |
| 2025-11-05 | $-0.36 | +2.7% | $5.00 | $4.62 | -7.6% |
| 2025-08-05 | $-0.41 | -17.1% | $5.80 | $5.48 | -5.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.30 | $-0.21 | +30.0% | $35.54M | +687.8% |
| 2025-09-30 | $-0.37 | $-0.36 | +2.7% | $5.17M | -80.2% |
| 2025-06-30 | $-0.35 | $-0.41 | -17.1% | $19.10M | +32.6% |
| 2025-03-31 | $-0.52 | $-0.50 | +3.1% | $14.74M | +9.3% |
| 2024-12-31 | $-0.42 | $-0.53 | -27.2% | $4.51M | -57.5% |
| 2024-09-30 | $-0.35 | $-0.34 | +2.9% | $26.08M | +158.2% |
| 2024-06-30 | $-0.40 | $-0.40 | +0.0% | $14.40M | +30.8% |
| 2024-03-31 | $-0.42 | $-0.39 | +7.1% | $13.49M | — |
| 2023-12-31 | $-0.45 | $-0.42 | +6.7% | $10.62M | — |
| 2023-09-30 | $-0.38 | $-0.43 | -13.2% | $10.10M | — |
| 2023-06-30 | $-0.37 | $-0.38 | -2.7% | $11.02M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2027 (E) | $-0.87 | $0.2B | +82.5% | 4 | high |
| 2028 (E) | $-0.65 | $0.2B | +60.0% | 4 | medium |
| 2029 (E) | $-0.35 | $0.4B | +50.0% | 4 | low |
| 2030 (E) | $0.25 | $0.5B | +40.0% | 4 | low |
Frequently asked questions
Has Recursion Pharmaceuticals Inc beaten earnings estimates?
Recursion Pharmaceuticals Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +4.7% over the last 4 quarters.
How does RXRX stock react to earnings?
RXRX stock has moved an average of -2.1% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Recursion Pharmaceuticals Inc's revenue growth rate?
Recursion Pharmaceuticals Inc reported year-over-year revenue growth of +687.8% in its most recent quarter, with EPS growing +60.4% year-over-year.
What is the expected EPS for RXRX in 2027?
Analysts expect Recursion Pharmaceuticals Inc to report EPS of $-0.87 for fiscal year 2027, on revenue of $0.2B, based on estimates from 4 analysts.